We are live on ! Find out more
RVPH

REVIVA PHARMA HLDGS INC

Delisted

RVPH was delisted on the 13th of May, 2026.

31 hedge funds and large institutions have $8.75M invested in REVIVA PHARMA HLDGS INC in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

180% more call options, than puts

Call options by funds: $492K | Put options by funds: $176K

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

11% more funds holding

Funds holding: 2831 (+3)

0.15% more ownership

Funds ownership: 1%1.15% (+0.15%)

58% less capital invested

Capital invested by funds: $21M → $8.75M (-$12.3M)

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
9
Increased
12
Reduced
4
Closed
5
Calls
$492K
Puts
$176K
Net Calls
+$316K
Net Calls Change
-$1.16M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Woodline Partners
California
$2.04M +$1.22M +26,889 +51%
Millennium Management
2
Millennium Management
New York
$1.59M +$879K +19,345 +45%
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.31M +$53.2K +1,170 +2%
SSA
4
Schonfeld Strategic Advisors
New York
$1.3M +$425K +9,360 +23%
PHP
5
Parkman Healthcare Partners
Connecticut
$646K +$1.68K +37 +0.1%
SM
6
Sabby Management
Florida
$303K +$539K +11,850 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$302K +$36.4K +800 +7%
Focus Partners Wealth
8
Focus Partners Wealth
Massachusetts
$206K -$22.7K -500 -6%
PAMP
9
Polar Asset Management Partners
Ontario, Canada
$198K
UBS Group
10
UBS Group
Switzerland
$170K +$283K +6,217 +1,535%
ECM
11
EMC Capital Management
Texas
$140K
BlackRock
12
BlackRock
New York
$132K +$25.2K +554 +12%
State Street
13
State Street
Massachusetts
$91.4K +$18.6K +410 +13%
Northern Trust
14
Northern Trust
Illinois
$73.9K +$16.6K +365 +14%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$52.5K -$458K -10,082 -83%
Two Sigma Investments
16
Two Sigma Investments
New York
$39.8K +$70.6K +1,553 New
SIS
17
Sound Income Strategies
Florida
$38.4K +$68.2K +1,500 New
Group One Trading
18
Group One Trading
Illinois
$37.6K +$66.8K +1,470 New
Morgan Stanley
19
Morgan Stanley
New York
$22.9K +$28K +615 +219%
NWM
20
NRI Wealth Management
California
$15.8K
BCM
21
BluePointe Capital Management
California
$13.3K
Northwestern Mutual Wealth Management
22
Northwestern Mutual Wealth Management
Wisconsin
$11.9K
WAM
23
Wolverine Asset Management
Illinois
$5.8K +$2.64K +58 +34%
Bank of America
24
Bank of America
North Carolina
$5.05K -$40.9K -899 -82%
Simplex Trading
25
Simplex Trading
Illinois
$3K +$5.5K +121 New

RVPH Hedge Fund Activity: Q2 2024 in Review

31 of the 6,930 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2024, worth a combined $8.75M — down 58% from $21M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new RVPH positions and 5 closed out — a net gain of 4 holders — while 12 added to existing stakes and 4 trimmed.

The largest buyer was Woodline Partners, adding an estimated $1.22M. The largest seller was Susquehanna International Group, cutting an estimated $458K.

  • 31 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2024, up from 28 in Q1 2024.
  • Funds reported $8.75M of REVIVA PHARMA HLDGS INC stock for Q2 2024, down 58% quarter-over-quarter.
  • 9 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2024 and 5 closed out, a net change of +4 holders.
  • The largest REVIVA PHARMA HLDGS INC buyer in Q2 2024 was Woodline Partners, an estimated $1.22M added.
  • The largest REVIVA PHARMA HLDGS INC seller in Q2 2024 was Susquehanna International Group, an estimated $458K sold.

Based on aggregated 13F filings for Q2 2024.